01 2Apicore Pharmaceuticals Private Limited
02 1Aurobindo Pharma Limited
03 1FRESENIUS KABI IPSUM SRL
04 7Hybio Pharmaceutical Co., Ltd. (Pingshan Factory)
05 1Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
06 1Lianyungang Runzhong Pharmaceutical Co., Ltd.
07 1Nanjing Xingyin Pharmaceutical Group Co. Ltd.
08 1PolyPeptide Laboratories (Sweden) AB
01 1DEGARELIX
02 1DEGARELIX ACETATE
03 2DEGARELIX ACETATE MANNITOL
04 1Degarelix
05 10Degarelix Acetate
01 10China
02 3India
03 1Sweden
04 1Switzerland
NDC Package Code : 42973-343
Start Marketing Date : 2022-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 42973-344
Start Marketing Date : 2022-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 59651-477
Start Marketing Date : 2020-08-03
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 14403-0019
Start Marketing Date : 2024-06-04
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 14403-0019
Start Marketing Date : 2024-07-17
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 14403-0019
Start Marketing Date : 2024-06-04
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 14403-0019
Start Marketing Date : 2024-07-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 14403-0019
Start Marketing Date : 2024-07-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 14403-0019
Start Marketing Date : 2024-07-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 14403-0019
Start Marketing Date : 2024-07-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
A Degarelix Acetate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Degarelix Acetate, including repackagers and relabelers. The FDA regulates Degarelix Acetate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Degarelix Acetate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Degarelix Acetate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Degarelix Acetate supplier is an individual or a company that provides Degarelix Acetate active pharmaceutical ingredient (API) or Degarelix Acetate finished formulations upon request. The Degarelix Acetate suppliers may include Degarelix Acetate API manufacturers, exporters, distributors and traders.
click here to find a list of Degarelix Acetate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Degarelix Acetate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Degarelix Acetate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Degarelix Acetate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Degarelix Acetate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Degarelix Acetate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Degarelix Acetate suppliers with NDC on PharmaCompass.
We have 8 companies offering Degarelix Acetate
Get in contact with the supplier of your choice:
LOOKING FOR A SUPPLIER?
